Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Fosmidomycin decreases membrane hopanoids and potentiates the effects of colistin on Burkholderia multivorans clinical isolates.

Malott RJ, Wu CH, Lee TD, Hird TJ, Dalleska NF, Zlosnik JE, Newman DK, Speert DP.

Antimicrob Agents Chemother. 2014 Sep;58(9):5211-9. doi: 10.1128/AAC.02705-14. Epub 2014 Jun 23.

2.

Identification of hopanoid biosynthesis genes involved in polymyxin resistance in Burkholderia multivorans.

Malott RJ, Steen-Kinnaird BR, Lee TD, Speert DP.

Antimicrob Agents Chemother. 2012 Jan;56(1):464-71. doi: 10.1128/AAC.00602-11. Epub 2011 Oct 17.

3.

Resistance of the Burkholderia cepacia complex to fosmidomycin and fosmidomycin derivatives.

Messiaen AS, Verbrugghen T, Declerck C, Ortmann R, Schlitzer M, Nelis H, Van Calenbergh S, Coenye T.

Int J Antimicrob Agents. 2011 Sep;38(3):261-4. doi: 10.1016/j.ijantimicag.2011.04.020. Epub 2011 Jul 2.

PMID:
21724375
4.

[Evaluation of in vitro antibacterial activity of fosmidomycin and its derivatives].

Shtannikov AV, Sergeeva EE, Biketov SF, Ostrovskiĭ DN.

Antibiot Khimioter. 2007;52(7-8):3-9. Russian.

PMID:
18986018
5.

A second target of the antimalarial and antibacterial agent fosmidomycin revealed by cellular metabolic profiling.

Zhang B, Watts KM, Hodge D, Kemp LM, Hunstad DA, Hicks LM, Odom AR.

Biochemistry. 2011 May 3;50(17):3570-7. doi: 10.1021/bi200113y. Epub 2011 Apr 11.

6.

Elucidation of the Burkholderia cenocepacia hopanoid biosynthesis pathway uncovers functions for conserved proteins in hopanoid-producing bacteria.

Schmerk CL, Welander PV, Hamad MA, Bain KL, Bernards MA, Summons RE, Valvano MA.

Environ Microbiol. 2015 Mar;17(3):735-50. doi: 10.1111/1462-2920.12509. Epub 2014 Jun 24.

PMID:
24888970
7.

Identification of synergists that potentiate the action of polymyxin B against Burkholderia cenocepacia.

Loutet SA, El-Halfawy OM, Jassem AN, López JM, Medarde AF, Speert DP, Davies JE, Valvano MA.

Int J Antimicrob Agents. 2015 Oct;46(4):376-80. doi: 10.1016/j.ijantimicag.2015.05.010. Epub 2015 Jun 22.

PMID:
26187366
8.

Synergy of fosmidomycin (FR-31564) and other antimicrobial agents.

Neu HC, Kamimura T.

Antimicrob Agents Chemother. 1982 Oct;22(4):560-3.

9.

In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa.

Di X, Wang R, Liu B, Zhang X, Ni W, Wang J, Liang B, Cai Y, Liu Y.

J Antibiot (Tokyo). 2015 Sep;68(9):551-5. doi: 10.1038/ja.2015.27. Epub 2015 Mar 25.

PMID:
25805069
10.

A demonstration of the susceptibility of clinical isolates obtained from cystic fibrosis patients to manuka honey.

Jenkins R, Wootton M, Howe R, Cooper R.

Arch Microbiol. 2015 May;197(4):597-601. doi: 10.1007/s00203-015-1091-6. Epub 2015 Feb 14.

11.

Combination antimicrobial susceptibility testing of Burkholderia cepacia complex: significance of species.

Abbott FK, Milne KE, Stead DA, Gould IM.

Int J Antimicrob Agents. 2016 Nov;48(5):521-527. doi: 10.1016/j.ijantimicag.2016.07.020. Epub 2016 Sep 12.

PMID:
27665523
12.

Rapid emergence of a ceftazidime-resistant Burkholderia multivorans strain in a cystic fibrosis patient.

Stokell JR, Gharaibeh RZ, Steck TR.

J Cyst Fibros. 2013 Dec;12(6):812-6. doi: 10.1016/j.jcf.2013.01.009. Epub 2013 Mar 9.

13.

In vitro susceptibility of Burkholderia vietnamiensis to aminoglycosides.

Jassem AN, Zlosnik JE, Henry DA, Hancock RE, Ernst RK, Speert DP.

Antimicrob Agents Chemother. 2011 May;55(5):2256-64. doi: 10.1128/AAC.01434-10. Epub 2011 Feb 14.

14.

In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases.

Santimaleeworagun W, Wongpoowarak P, Chayakul P, Pattharachayakul S, Tansakul P, Garey KW.

Southeast Asian J Trop Med Public Health. 2011 Jul;42(4):890-900.

PMID:
22299471
15.

Crystal structures of the Burkholderia multivorans hopanoid transporter HpnN.

Kumar N, Su CC, Chou TH, Radhakrishnan A, Delmar JA, Rajashankar KR, Yu EW.

Proc Natl Acad Sci U S A. 2017 Jun 20;114(25):6557-6562. doi: 10.1073/pnas.1619660114. Epub 2017 Jun 5.

16.

In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates.

Vidaillac C, Benichou L, Duval RE.

Antimicrob Agents Chemother. 2012 Sep;56(9):4856-61. doi: 10.1128/AAC.05996-11. Epub 2012 Jul 2.

18.

Activity of Tobramycin against Cystic Fibrosis Isolates of Burkholderia cepacia Complex Grown as Biofilms.

Kennedy S, Beaudoin T, Yau YC, Caraher E, Zlosnik JE, Speert DP, LiPuma JJ, Tullis E, Waters V.

Antimicrob Agents Chemother. 2015 Oct 26;60(1):348-55. doi: 10.1128/AAC.02068-15.

19.

Variation of the antimicrobial susceptibility profiles of Burkholderia cepacia complex clonal isolates obtained from chronically infected cystic fibrosis patients: a five-year survey in the major Portuguese treatment center.

Leitão JH, Sousa SA, Cunha MV, Salgado MJ, Melo-Cristino J, Barreto MC, Sá-Correia I.

Eur J Clin Microbiol Infect Dis. 2008 Nov;27(11):1101-11. doi: 10.1007/s10096-008-0552-0. Epub 2008 Jul 4.

PMID:
18600352
20.

In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.

Rodríguez-Avial I, Pena I, Picazo JJ, Rodríguez-Avial C, Culebras E.

Int J Antimicrob Agents. 2015 Dec;46(6):616-21. doi: 10.1016/j.ijantimicag.2015.07.021. Epub 2015 Sep 9.

PMID:
26391381

Supplemental Content

Support Center